

Volume 74 (2018)

Supporting information for article:

Membrane protein crystals for neutron diffraction

Thomas Lykke-Møller Sørensen, Samuel John Hjorth-Jensen, Esko Oksanen, Jacob Lauwring Andersen, Claus Olesen, Jesper Vuust Moller and Poul Nissen

PDB	Protein	Resolution (Å)	Space group	a, b, c (Å)	α, β, γ (°)	Reference
4BVM	Human myelin peripheral membrane protein P2	0.93	P 4 <sub>1</sub> 2 <sub>1</sub> 2	58.07, 58.07, 101.50	90.00, 90.00, 90.00	(Laulumaa <i>et al.</i> , 2015)
5JAE	$LeuT_{Aa}$ leucine transporter	1.65	P 2 <sub>1</sub>	81.57, 92.08, 92.47	90.00, 95.18, 90.00	(Yamashit a <i>et al.</i> , 2005)
4US3	MhsT multi-hydrolphobic amino acid transporter	2.1	P 2	44.28, 49.89, 110.05	90.00, 96.76, 90.00	(Malinausk aite <i>et al.</i> , 2014)
4AV3	Na <sup>+</sup> -translocating M-PPase with metal ions in active site	2.6	P 2 <sub>1</sub>	83.52, 107.78, 102.52	90.00, 108.50, 90.00	(Kellosalo <i>et al.</i> , 2012)
5NG9	Glutamate receptor 2	1.15	P 2 <sub>1</sub> 2 <sub>1</sub> 2	62.22, 88.14, 47.96	90.00, 90.00, 90.00	(Mollerud <i>et al.</i> , 2017)
2W2E	Aqy1 yeast aquaporin (pH 3.5)	1.15	I 4	91.45, 91.45, 80.82	90.00, 90.00, 90.00	(Fischer <i>et</i> <i>al.</i> , 2009)
2NTU	Bacteriorhodopsin	1.53	P 6 <sub>3</sub>	60.97, 60.97, 110.39	90.00, 90.00, 120.00	(Lanyi & Schobert, 2007)
3HB3	Cytochrome C Oxidase	2.25	P 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	83.40, 150.47, 157.19	90.00, 90.00, 90.00	(Koepke <i>et</i> <i>al.</i> , 2009)
2J8C	Photosynthetic Reaction Center	1.9	P 3 <sub>1</sub> 2 1	138.69, 138.69, 184.61	90.00, 90.00, 120.00	(Koepke <i>et</i> <i>al.</i> , 2007)
3C1J	AmtB (ammonia channel)	2.0	P6 <sub>3</sub>	110.23, 110.23, 84.64	90.00, 90.00, 120.00	(Javelle <i>et</i> <i>al.</i> , 2008)

## **Table S1**Favourable membrane protein cases suitable for NMX


5WIU	Dopamine D <sub>4</sub> receptor complexed with nemonapride	2.0	C 2 2 2 <sub>1</sub>	67.69, 164.05, 84.13	90.00, 90.00, 90.00	(Wang <i>et</i> <i>al.</i> , 2017)
6EU6	Sensor Amt Protein	2.0	P 6 <sub>3</sub>	99.75, 99.75, 89.07	90.00, 90.00, 120.00	(Pfluger <i>et</i> <i>al.</i> , 2018)
4RYQ	Translocator Protein (TSPO), apo type 2 monomer	1.7	P 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	28.71, 54.62, 106.91	90.00, 90.00, 90.00	(Guo <i>et al.</i> , 2015)
3TDO	FNT3 Hydrosulphide Channel (HSC), pH 9.0	2.2	P 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	98.82, 118.74, 149.82	90.00, 90.00, 90.00	(Czyzewsk i & Wang, 2012)

PDB	Crystal Form	Resolution (Å)	Space group	a, b, c (Å)	α, β, γ (°)	Ligands	Reference
1T5S	Ca2E1•AMPPC P	2.6	C 1 2 1	162.44, 76.26, 151.16	90.00, 108.70, 90.00	AMPPCP, Ca2+, K+, Mg2+	(Sorensen <i>et</i> <i>al.</i> , 2004)
1XPS	E2(TG)•AlF4-	3.0	P 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	86.51, 119.27, 142.26	90.00, 90.00, 90.00	Thapsigargin, AlF4, K+, Mg2+	(Olesen <i>et</i> <i>al.</i> , 2004)
1T5T	Ca2E1•AlF4- •ADP	2.9	C 1 2 1	162.48, 75.62, 151.65	90.00, 108.82, 90.00	ADP, AlF4, Ca2+, K+, Mg2+	(Sorensen <i>et</i> <i>al.</i> , 2004)
2C9M	Ca2E1	3.0	P 1	64.95, 81.28, 131.01	97.64, 99.94, 95.22	Ca2+, K+, Cl-	(Jensen <i>et</i> <i>al.</i> , 2006)
209J	E2(CPA)•MgF4 2-	2.65	C 1 2 1	175.38, 69.88, 143.41	90.00, 107.10, 90.00	CPA, MgF4-, Mg2+, Na+	(Moncoq <i>et</i> <i>al.</i> , 2007)
20A0	E2(CPA)•ADP	3.4	P 1 2 <sub>1</sub> 1	62.50, 96.84, 154.86	90.00, 94.83, 90.00	ADP, CPA, Mg2+	(Moncoq <i>et</i> <i>al.</i> , 2007)
2EAR	E2(TG)	3.1	P 1 2 <sub>1</sub> 1	62.85, 95.94, 154.49	90.00, 94.90, 90.00	Thapsigargin	(Takahashi <i>et al.</i> , 2007)
2EAT	E2(TG+CPA)	2.9	P 1 2 <sub>1</sub> 1	62.90, 95.64, 155.10	90.00, 95.24, 90.00	Thapsigargin, CPA	(Takahashi <i>et al.</i> , 2007)
2ZBF	E2(TG)•BeF3-	2.4	P 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	90.52, 136.47, 106.62	90.00, 90.00, 90.00	Thapsigargin, BeF3-, Mg2+	(Toyoshima et al., 2007)
2ZBG	E2(TG)•AlF4-	2.55	C 1 2 1	117.50, 70.20, 143.40	90.00, 106.80, 90.00	Thapsigargin, AlF4-, Mg2+	(Toyoshima et al., 2007)


## **Table S2**Favourable SERCA crystal forms for NMX

3B9R	E2(TG)•AlF4 AMPPCP	3.0	P 1 2 <sub>1</sub> 1	131.98, 94.43, 136.18	90.00, 107.79, 90.00	AMPPCP, AlF4-, K+, Mg2+	(Olesen <i>et</i> <i>al.</i> , 2007)
3BA6	Ca2E1~P•AMP PN	2.8	C 1 2 1	162.51, 75.97, 152.41	90.00, 109.01, 90.00	AMP Phosphoramidate, Ca2+, K+	(Olesen <i>et</i> <i>al.</i> , 2007)
3FPB 2O9J	E2(CPA)•MgF4 2-•ATP	2.55	C 1 2 1	175.36, 69.87, 143.50	90.00, 107.16, 90.00	ATP, CPA, MgF42-, K+, Mg2+	(Laursen <i>et</i> <i>al.</i> , 2009)
3FPS 2OA0	E2(CPA)•ADP	3.2	P 1 2 <sub>1</sub> 1	62.34, 96.50, 155.13	90.00, 94.84, 90.00	ADP, CPA, Mg2+	(Laursen <i>et</i> <i>al.</i> , 2009)
3AR8	E2(TG)•AlF4- •TNP-AMP	2.6	C 1 2 1	176.86, 69.87, 141.81	90.00, 106.71, 90.00	Thapsigargin, TNP-AMP, AlF4-, Mg2+, Na+	(Toyoshima <i>et al.</i> , 2011)
3AR9	E2(TG)-BeF3- •TNP-AMP	2.6	P 2 <sub>1</sub> 2 <sub>1</sub> 2	90.39, 135.81, 105.43	90.00, 90.00, 90.00	Thapsigargin, TNP-AMP, BeF3-, Mg2+, Na+	(Toyoshima <i>et al.</i> , 2011)
4YCL	E2(CPA)	3.25	P 1 2 <sub>1</sub> 1	63.04, 96.03, 155.42	90.00, 95.09, 90.00	CPA, K+, Mg2+	(Takahashi <i>et al.</i> , 2007)
5A3Q	E2(TG)•VO3- •TNP-AMPPCP	3.05	P 2 <sub>1</sub> 2 <sub>1</sub> 2	86.43, 118.78, 141.83	90.00, 90.00, 90.00	TNP-AMPPCP, Thapsigargin,vana dium, K+, Cl-, Mg2+	(Clausen <i>et</i> <i>al.</i> , 2016)
5A3S	E2(TG)•VO3- •TNP-ATP	3.3	P 1 2 <sub>1</sub> 1	130.56, 93.78, 135.69	90.00, 107.26, 90.00	TNP-ATP, Thapsigargin,vana dium, K+, Cl-, Mg2+	(Clausen <i>et</i> <i>al.</i> , 2016)
5XA7	Ca2E1	3.2	C 1 2 1	166.20, 64.54, 146.22	90.00, 98.12, 90.00	1,2-dioleoyl-SN- glycero-3- phosphocholine, Ca2+, Na+	(Norimatsu et al., 2017)
5XA8	Ca2E1•AlF4- •ADP	3.2	C 1 2 1	162.97, 75.02, 152.24	90.00, 109.31, 90.00	1,2-dioleoyl-SN- glycero-3- phosphocholine,	(Norimatsu et al., 2017)


ADP, AlF4-,Ca2+, Mg2+




**Figure S1** Decoupling nucleation and growth phases. Nucleation (i) occurs at typical (< 5  $\mu$ L) drop volumes over a period of ~24 hours (before crystals develop beyond infancy). A high volume of protein-rich solution is added to the initial drop, bringing the combined conditions into the  $\uparrow$  [protein] /  $\downarrow$  [precipitant] area of the metastable zone (ii). Protein concentration drops as a few nuclei survive to become fully-fledged crystals and the mother liquor proceeds towards the solubility line (iii). Careful selection of reservoir composition and volume keeps the mother liquid in the metastable phase – counteracting the loss of [protein] due to crystal growth by increasing [precipitant] *via* vapour diffusion – and results in crystals of maximal size when the solubility line is reached (iv). As crystal growth occurs along a smooth and uninterrupted phase-time pathway, diffraction quality should be maximised.




**Figure S2** Dynamics of counter-diffusion crystallisation. Initially, a supersaturation wave moves along the capillary, sporadically crossing the nucleation threshold and forming nuclei (**i**). Afterwards, a more stable [precipitant] gradient combines with the remaining pockets of high (and varying) supersaturation, and nuclei develop into a mixture of crystal polymorphs and precipitates (**ii**). This gradient slowly moves through the capillary, counteracting the drive towards the solubility line as protein leaves the solution as precipitate or crystal growth (**iii**). Excessive [precipitant] near the physical buffer forces all excess protein to drop out as precipitate, and the mother liquor reaches the solubility limit. Further along the capillary, [precipitant] is more optimal, keeping the mother liquor within the metastable (growth) zone and resulting in large crystals. The red/orange colour inside capillaries indicates that various amounts of protein precipitation is normally observed.




**Figure S3** Mounting single SERCA crystals in capillary. Capillary bottoms were first sealed with wax (i), before batch solution was injected into the middle of the capillary – leaving an air gap above and below the batch solution – and the capillary top was sealed with immersion oil (ii). After a period of  $\sim$ 2 weeks, a few single crystals developed within the batch solution (iii). A suitable crystal was selected, the immersion oil plug removed, and a smaller capillary was inserted into the crystal-containing capillary (iv). This smaller capillary was used to suck out the mother liquor surrounding the crystal, after which it was removed and the crystal-containing capillary re-sealed with immersion oil (v). The isolated crystal was now ready to be mounted directly onto the X-ray goniometer for diffraction studies.



**Figure S4** Diffraction image. The maximum diffraction of the tested Ca<sub>2</sub>E1-AMPPCP crystals was  $\sim$ 3.0 Å. The frame shown is of an initial test shot of comprising a 0.5 ° rotation over a 35 s exposure.



**Figure S5** Examples of radiation sensitivity. Images  $\mathbf{i} - \mathbf{iv}$  (corresponding to frames 1, 60, 120, and 180 respectively) show the loss of diffraction quality over time. Each frame comprised of a 0.5 ° rotation over a 35 s exposure, meaning maximum resolution deteriorated from ~3.5 Å ( $\mathbf{i}$ ) to ~8 Å ( $\mathbf{iii}$ ) over a time period of only 70 mins.



**Figure S6** Temperature-dependent perturbation of the SERCA1 structure. The distances from each atom in the structures to the protein centre-of-mass is compared for the RT (6hef) and cryo (3n8g) structures. The histogram shows the distribution of the differences in distance for equivalent atoms in the two structures (mean=0.26, SD=0.91).